vs

Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and MEDIFAST INC (MED). Click either name above to swap in a different company.

BYLINE BANCORP, INC. is the larger business by last-quarter revenue ($112.4M vs $75.1M, roughly 1.5× MEDIFAST INC). On growth, BYLINE BANCORP, INC. posted the faster year-over-year revenue change (9.0% vs -36.9%). Over the past eight quarters, BYLINE BANCORP, INC.'s revenue compounded faster (6.4% CAGR vs -34.4%).

Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

BY vs MED — Head-to-Head

Bigger by revenue
BY
BY
1.5× larger
BY
$112.4M
$75.1M
MED
Growing faster (revenue YoY)
BY
BY
+45.9% gap
BY
9.0%
-36.9%
MED
Faster 2-yr revenue CAGR
BY
BY
Annualised
BY
6.4%
-34.4%
MED

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BY
BY
MED
MED
Revenue
$112.4M
$75.1M
Net Profit
$37.6M
Gross Margin
69.4%
Operating Margin
-10.4%
Net Margin
33.4%
Revenue YoY
9.0%
-36.9%
Net Profit YoY
33.0%
EPS (diluted)
$0.83
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BY
BY
MED
MED
Q1 26
$112.4M
Q4 25
$117.0M
$75.1M
Q3 25
$115.7M
$89.4M
Q2 25
$110.5M
$105.6M
Q1 25
$103.1M
$115.7M
Q4 24
$104.7M
$119.0M
Q3 24
$101.8M
$140.2M
Q2 24
$99.4M
$168.6M
Net Profit
BY
BY
MED
MED
Q1 26
$37.6M
Q4 25
$34.5M
Q3 25
$37.2M
$-2.3M
Q2 25
$30.1M
$2.5M
Q1 25
$28.2M
$-772.0K
Q4 24
$30.3M
Q3 24
$30.3M
$1.1M
Q2 24
$29.7M
$-8.2M
Gross Margin
BY
BY
MED
MED
Q1 26
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Operating Margin
BY
BY
MED
MED
Q1 26
Q4 25
40.1%
-10.4%
Q3 25
43.1%
-4.6%
Q2 25
35.2%
-1.0%
Q1 25
36.4%
-1.1%
Q4 24
38.6%
0.6%
Q3 24
39.3%
1.5%
Q2 24
40.4%
-4.7%
Net Margin
BY
BY
MED
MED
Q1 26
33.4%
Q4 25
34.1%
Q3 25
32.1%
-2.5%
Q2 25
27.2%
2.3%
Q1 25
27.4%
-0.7%
Q4 24
34.3%
Q3 24
29.8%
0.8%
Q2 24
29.9%
-4.8%
EPS (diluted)
BY
BY
MED
MED
Q1 26
$0.83
Q4 25
$0.77
$-1.64
Q3 25
$0.82
$-0.21
Q2 25
$0.66
$0.22
Q1 25
$0.64
$-0.07
Q4 24
$0.68
$0.08
Q3 24
$0.69
$0.10
Q2 24
$0.68
$-0.75

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BY
BY
MED
MED
Cash + ST InvestmentsLiquidity on hand
$198.4M
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.3B
$198.9M
Total Assets
$9.9B
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BY
BY
MED
MED
Q1 26
$198.4M
Q4 25
$149.1M
$167.3M
Q3 25
$259.0M
$173.5M
Q2 25
$218.3M
$162.7M
Q1 25
$421.3M
$164.6M
Q4 24
$563.1M
$162.3M
Q3 24
$452.6M
$170.0M
Q2 24
$730.5M
$163.5M
Stockholders' Equity
BY
BY
MED
MED
Q1 26
$1.3B
Q4 25
$1.3B
$198.9M
Q3 25
$1.2B
$214.7M
Q2 25
$1.2B
$216.0M
Q1 25
$1.1B
$211.0M
Q4 24
$1.1B
$210.1M
Q3 24
$1.1B
$207.3M
Q2 24
$1.0B
$205.3M
Total Assets
BY
BY
MED
MED
Q1 26
$9.9B
Q4 25
$9.7B
$248.0M
Q3 25
$9.8B
$268.2M
Q2 25
$9.7B
$269.3M
Q1 25
$9.6B
$280.0M
Q4 24
$9.5B
$284.2M
Q3 24
$9.4B
$291.2M
Q2 24
$9.6B
$293.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BY
BY
MED
MED
Operating Cash FlowLast quarter
$-5.3M
Free Cash FlowOCF − Capex
$-6.6M
FCF MarginFCF / Revenue
-8.8%
Capex IntensityCapex / Revenue
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BY
BY
MED
MED
Q1 26
Q4 25
$140.3M
$-5.3M
Q3 25
$38.3M
$12.1M
Q2 25
$16.3M
$-3.4M
Q1 25
$27.1M
$3.4M
Q4 24
$175.2M
$-4.9M
Q3 24
$19.8M
$9.1M
Q2 24
$40.1M
$13.1M
Free Cash Flow
BY
BY
MED
MED
Q1 26
Q4 25
$136.3M
$-6.6M
Q3 25
$38.0M
$10.8M
Q2 25
$15.2M
$-4.8M
Q1 25
$25.0M
$1.9M
Q4 24
$171.2M
$-7.2M
Q3 24
$19.1M
$7.7M
Q2 24
$39.4M
$11.1M
FCF Margin
BY
BY
MED
MED
Q1 26
Q4 25
116.5%
-8.8%
Q3 25
32.8%
12.0%
Q2 25
13.7%
-4.5%
Q1 25
24.3%
1.6%
Q4 24
163.5%
-6.1%
Q3 24
18.8%
5.5%
Q2 24
39.7%
6.6%
Capex Intensity
BY
BY
MED
MED
Q1 26
Q4 25
3.4%
1.8%
Q3 25
0.3%
1.5%
Q2 25
1.0%
1.3%
Q1 25
2.0%
1.3%
Q4 24
3.8%
1.9%
Q3 24
0.6%
1.0%
Q2 24
0.7%
1.1%
Cash Conversion
BY
BY
MED
MED
Q1 26
Q4 25
4.06×
Q3 25
1.03×
Q2 25
0.54×
-1.36×
Q1 25
0.96×
Q4 24
5.78×
Q3 24
0.65×
8.04×
Q2 24
1.35×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons